Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- Check3 days agoChange DetectedAdded a citation to iRECIST guidelines in the references and removed the corresponding erratum note.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.5.0 was added to the page. Revision: v3.4.3 was removed from the page.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedUpdated the iRECIST guideline reference to the Lancet Oncol 2017 guidelines (version 3.4.3), replacing the older 3.4.2 citation.SummaryDifference0.1%

- Check52 days agoChange DetectedMinor version update from v3.4.1 to v3.4.2; study details and page layout remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page revision label changed from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check82 days agoChange DetectedRevision history updated: added Revision: v3.3.4 and removed Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.